Figure S1. Effect of ECL on $p^{(S473)}$-AKT and total AKT expression in human NSCLC cells. The relative expression of (A and C) $p^{(S473)}$-AKT and (B and D) total AKT normalized to β-actin in whole cell extracts of the A549 and Calu-1 cells treated with ECL at the IC_{20}, IC_{40}, and IC_{50} concentrations for 24 h. β-actin was used as an internal control. Data are presented as the mean values ± SD. *$P<0.05$, **$P<0.01$, ***$P<0.001$ vs. the untreated control group. ECL, eurycomalactone; AKT, protein kinase B; NSCLC, non-small cell lung cancer.

Figure S2. Effect of ECL on $p^{(S536)}$-NF-κB p65 and total NF-κB p65 expression in human NSCLC cells. The relative expression of (A and C) $p^{(S536)}$-NF-κB p65 and (B and D) total NF-κB p65 normalized to β-actin in whole cell extracts of the A549 cells and Calu-1 cells treated with ECL at the IC_{20}, IC_{40}, and IC_{50} concentrations for 24 h. β-actin was used as an internal control. Data are presented as the mean values ± SD. *$P<0.05$, **$P<0.01$, ***$P<0.001$ vs. the untreated control group. ECL, eurycomalactone; NF-κB, nuclear factor-κB; NSCLC, non-small cell lung cancer.